2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Stearoyl-CoA Desaturase (SCD)

Stearoyl-CoA Desaturase (SCD)

Stearoyl-CoA Desaturase (SCD)

Related Products

PDF 0.22 MB

Stearoyl-CoA desaturase (SCD) is a key regulator of membrane fluidity, turns over rapidly, and represents a model for selective degradation of short-lived proteins of the endoplasmic reticulum (ER). SCD is a rate-limiting lipogenic enzyme that plays an integral role in catalyzing the synthesis of monounsaturated fatty acids, chiefly oleate and palmitoleate. Both contribute a major part of the biological membrane. Numerous SCD isoforms exist in mouse and humans, i.e., SCD-1 to SCD-4 and SCD-1 and SCD-5, respectively.

Overexpression of SCD is evident and implicated in metabolic diseases such as diabetes and non-alcoholic fatty liver disease. SCD also stimulates canonical Wnt pathway and YAP activation in support of stemness and tumorigenesis. SCD facilitates metabolic reprogramming in cancer which is mediated, at least in part, by regulation of AKT, AMPK, and NF-kB via MUFAs. From the biological viewpoint, hyperexpression of SCD1 causes many metabolic disorders including obesity, insulin resistance, hypertension, and hypertriglyceridemia, etc. SCD1 is a pharmacological target in the treatment of obesity, diabetes and other metabolic diseases.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-50709
    A939572
    		Inhibitor 99.98%
    A939572 is a potent, and orally bioavailable stearoyl-CoA desaturase1 (SCD1) inhibitor with IC50 values of <4 nM and 37 nM for mSCD1 and hSCD1, respectively.
    A939572
  • HY-15823
    CAY10566
    		Inhibitor 99.82%
    CAY10566 is a potent, orally bioavailable and selective stearoyl-CoA desaturase1 (SCD1) inhibitor with IC50s of 4.5 and 26 nM in mouse and human enzymatic assays, respectively. CAY10566 also shows excellent cellular activity in blocking the conversion of saturated long-chain fatty acid-CoAs (LCFA-CoAs) to monounsaturated LCFA-CoAs in HepG2 cells (IC50=7.9 nM or 6.8 nM).
    CAY10566
  • HY-13070
    MK-8245
    		Inhibitor 99.04%
    MK-8245 is a potent, liver-targeted stearoyl-CoA desaturase (SCD) inhibitor, with IC50s of 1 nM for human SCD1 and 3 nM for both rat SCD1 and mouse SCD1, with antidiabetic and antidyslipidemic efficacy.
    MK-8245
  • HY-19796
    Icomidocholic acid
    		≥99.0%
    Icomidocholic acid (Aramchol) is a conjugate of cholic acid and arachidic acid that could inhibit stearoyl coenzyme A desaturase 1 (SCD1) activity. Icomidocholic acid has potential use in nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) treatment.
    Icomidocholic acid
  • HY-15822
    MF-438
    		Inhibitor 99.92%
    MF-438 is a potent and orally bioavailable stearoyl-CoA desaturase 1 (SCD1) inhibitor with an IC50 of 2.3 nM for rSCD1.
    MF-438
  • HY-111315
    XEN103
    		Inhibitor
    XEN103 is a SCD1 inhibitor, with IC50s of 14 nM and 12 nM for mSCD1 and SCD1 in HepG2 cell. XEN103 can be used for research of obesity and type 2 diabetes. XEN103 also induces sebaceous gland atrophy in mice.
    XEN103
  • HY-114527
    TPMP-I-2
    		Inhibitor
    TPMP-I-2 is an anticancer agent that induces cancer cell lines Apoptosis and decreases protein levels of stearoyl-CoA desaturase. TPMP-I-2 prolongs the survival time of nude rats in a simulated micrometastatic cervical cancer model and reduces tumor growth in a breast cancer model in nude mice combined with immunotoxins.
    TPMP-I-2
  • HY-155209
    SCD1 inhibitor-5
    		Inhibitor
    SCD1 inhibitor-5 (compound 51) is a SCD1 inhibitor,with the IC50 values​ of 0.13 μM and 31 μM for H2122 and H1819, respectively. SCD1 inhibitor-5 can be used in cancer research.
    SCD1 inhibitor-5
  • HY-15700
    PluriSIn 1
    		Inhibitor 99.84%
    PluriSIn 1 (NSC 14613) is an inhibitor of stearoyl-coA desaturase (SCD), and is a pluripotent cell-specific inhibitor.
    PluriSIn 1
  • HY-12756A
    E6446 dihydrochloride
    		Inhibitor 99.96%
    E6446 dihydrochloride is a potent and orally acitve TLR7 and TLR9 antagonist, used in the research of deleterious inflammatory responses. E6446 dihydrochloride is also a potent SCD1 inhibitor (KD: 4.61 μM), significantly inhibiting adipogenic differentiation and hepatic lipogenesis through SCD1-ATF3 signaling. E6446 dihydrochloride also improves liver pathology in high-fat diet (HFD)-fed mice and may be useful in the study of non-alcoholic fatty liver disease (NAFLD).
    E6446 dihydrochloride
  • HY-124751
    YTX-465
    		Inhibitor 99.06%
    YTX-465 is a stearoyl-CoA desaturase (Ole1/SCD) inhibitor. YTX-465 inhibits Ole1 and SCD1 with IC50s of 0.039 μM and 30.4 μM, respectively. YTX-465 can be used in the research of Parkinson’s disease and other synucleinopathies.
    YTX-465
  • HY-19762
    GSK1940029
    		Inhibitor 99.82%
    GSK1940029 (SCD inhibitor 1) is a stearoyl-coa desaturase (SCD) inhibitor extracted from patent WO/2009060053 A1, compound example 16.
    GSK1940029
  • HY-N6807
    Elemicin
    		Inhibitor 99.22%
    Elemicin is an orally active alkenylbenzene widely distributed in many herbs and spices. Elemicin inhibits Stearoyl-CoA Desaturase 1 (SCD1) by metabolic activation. Elemicin has anti-influenza activities, antimicrobial, antioxidant, and antiviral activities. Elemicin and its reactive metabolite of 1′-Hydroxyelemicin can induce hepatotoxicity.
    Elemicin
  • HY-100249
    XEN723
    		Inhibitor 99.90%
    XEN723 is a novel and potent thiazolylimidazolidinone inhibitor of Stearoyl-CoA Desaturase (SCD1) with IC50s of 45 and 524 nM in mouse and HepG2 cell, respectively.
    XEN723
  • HY-127143
    Sterculic acid
    		Inhibitor ≥99.0%
    Sterculic acid is a stearoyl-CoA desaturase-1 (SCD1) inhibitor. Sterculic acid specifically inhibits the delta-9 desaturase (Δ9D) activity with an IC50 value of 0.9 μM.
    Sterculic acid
  • HY-141525
    SCD1 inhibitor-4
    		Inhibitor 98.93%
    SCD1 inhibitor-4 is a potent, orally active stearoylCoA desaturase-1 (SCD1) inhibitor. SCD1 inhibitor-4 can be used for the research of diabetes.
    SCD1 inhibitor-4
  • HY-155033
    SSI-4
    		Inhibitor 99.95%
    SSI-4 is an inhibitor of Stearoyl CoA desaturase 1 (SCD1) , which can be modified with 11C, used as a ligand to in vivo small animal PET/CT imaging of SCD1.
    SSI-4
  • HY-11034
    CVT-12012
    		Inhibitor 99.16%
    CVT-12012 is a potent and orally bioavailable stearoyl-coA desaturase (SCD) inhibitor, with IC50s of 38 nM, 6.1 nM for rat microsomal and human HEPG2, respectively.
    CVT-12012
  • HY-113638
    CVT-11127
    		Inhibitor 99.88%
    CVT-11127 is a potent SCD inhibitor. CVT-11127 induces apoposis and arrests the cell cycle at the G1/S phase. CVT-11127 has the potential for the research of lung cancer.
    CVT-11127
  • HY-12756
    E6446
    		Inhibitor ≥98.0%
    E6446 is a potent and orally acitve TLR7 and TLR9 antagonist, used in the research of deleterious inflammatory responses. E6446 is also a potent SCD1 inhibitor (KD: 4.61 μM), significantly inhibiting adipogenic differentiation and hepatic lipogenesis through SCD1-ATF3 signaling. E6446 also improves liver pathology in high-fat diet (HFD)-fed mice and may be useful in the study of non-alcoholic fatty liver disease (NAFLD).
    E6446
Cat. No. Product Name / Synonyms Application Reactivity